Recent Headlines
Within Biotechnology
Clinical Guidelines for Physical Therapy in Huntington Disease
HSG Announces Publication of Clinical Guidelines for Physical Therapy in Huntington Disease - February 27, 2020 - Huntington Study Group
Recombinetics Announces Collaboration with University of Texas Southwestern to Advance Regenerative Medicine Through Therapeutic Cell, Tissue, and Organ Production
Recombinetics (RCI) today announced a collaborative research project with University of Texas Southwestern (UTSW) to identify key factors that improve the efficiency of generating interspecies chimera between pigs and humans. This near-term goal will benefit the long-term objective of advancing... - February 27, 2020 - Recombinetics, Inc.
BioStat Solutions, Inc. Promotes Dr. Lin Li to Senior Director of Scientific Operations
BioStat Solutions, Inc. (BSSI), a data analytics company providing consulting services to pharmaceutical and biotechnology companies, announced today the promotion of Dr. Lin Li to Senior Director of Scientific Operations. He will have increased responsibility leading the scientific team and... - February 10, 2020 - BioStat Solutions, Inc.
MedBiome Licenses the RapidAIM Technology Targeting the Microbiome to Improve Human Health
MedBiome accelerates the development of drugs targeting the gut microbiome. The RapidAIM technology enables rapid screening of the effects of compounds on live individual human microbiomes in 96 well plates. - January 30, 2020 - MedBiome
MoBiTec to Offer Novel Coronavirus (2019-nCoV) Real Time RT-PCR Kit
Novel Coronavirus (2019-nCoV) Real Time RT-PCR Kit is used for the qualitative detection of a novel coronavirus, identified in 2019 in Wuhan City, China, in respiratory tract specimens by real time PCR systems. - January 25, 2020 - MoBiTec GmbH
ALS Therapy Development Institute Announces Naming of Augie’s Quest Translational Research Center
“It’s really incredible. For 15 years, Augie’s Quest has been dedicated to raising the critical funds and broad awareness needed to help fast-track ALS TDI’s cutting-edge ALS research – specifically providing ALS TDI with more than $150 million to advance its efforts to end ALS,” commented Steven Perrin Ph.D., CEO of ALS TDI. - January 24, 2020 - ALS Therapy Development Institute
The International Division of The MAGIC Foundation®, ICOSEP Welcomes MAGIC Africa to Their Network
ICOSEP welcomes MAGIC Africa to their network of organizations. The network is comprised of patient organizations, professional societies and volunteers, who are uniting their voices for endocrine awareness. - January 17, 2020 - ICOSEP
3Sixty Pharma Solutions Partners with Westchester Biotech Project
Leveraging its “360Start-Up” Powerhouse to Grow a Dynamic Non-Profit for Scientists - January 11, 2020 - 3Sixty Pharma Solutions
New NF-kB Panel of Antibodies from AbboMax and Human Diseases
NF-kB is a protein complex that controls the transcription of DNA. It is a heterodimer sequestered in the cytoplasm. In response to activation NF-kB translocates to the nucleus to 'turn on' the expression of specific genes that keeps a cell proliferating and protects it from apoptosis. AbboMax has developed a panel of NF-kB related antibodies. - December 22, 2019 - AbboMax, Inc.
ALS TDI Collaboration with Google’s Project Euphonia Highlighted in Documentary Series Featuring Former NFL Player Tim Shaw “The Age of A.I.” Hosted by Robert Downey Jr.
The ALS Therapy Development Institute (ALS TDI), the world’s foremost drug discovery lab focused solely on finding treatments and cures for ALS, today proudly announced that it is featured in episode two of “The Age of A.I.,” a new YouTube Originals documentary series that takes... - December 18, 2019 - ALS Therapy Development Institute
3Sixty Pharma Solutions Announces Successful Submission of Start-Up Biotech Investigational New Drug Application
3Sixty Pharma Solutions LLC, www.3sixtypharma.com, last week announced the successful submission to FDA of its first Investigational New Drug (IND) Application on behalf of one of its start-up biotech clients. This news comes on the heels of the formal organization in 2018 of 3Sixty Pharma... - December 16, 2019 - 3Sixty Pharma Solutions
ALS Therapy Development Institute Reflects on the Impact of Pete Frates and the Ice Bucket Challenge
On Monday it was announced that Pete Frates passed away due to complications from ALS. Pete was a leader in the ALS community and the inspiration for the Ice Bucket Challenge, which helped raise millions of dollars for ALS research and awareness. Though it has been five years since the Challenge,... - December 11, 2019 - ALS Therapy Development Institute
BoneScience Will Soon Launch Its Newly Developed Product Dr’s Grow UP
The teenage years are an important and exciting time in our life. Our body goes through a lot of change and emotions play an important role. Body height, as well as physical appearance, become often important factors for teen self-esteem. They take influence on friendships, school, and dating... - December 09, 2019 - Redmars America Co., Ltd.
Virun® Making an Impact at PGA Show January 2020
Virun® will be amongst the 1,000+ interactive exhibitors attending the PGA Merchandise Show in Orlando, Florida January 21 through January 24. - December 06, 2019 - VIRUN
RetroMAD1, the World's First Antiviral Protein, Saves Cats Suffering from Feline Leukemia, a Disease Once Thought Incurable
Biovalence Technologies owns a proprietary recombinant proteomic technology platform that covers around 100 different proteins with potential antiviral therapeutic. The company’s mission is to save lives by applying recent advancement in genomics and proteomics on infectious diseases that have no cure today. - December 05, 2019 - Biovalence Technologies Pte Ltd
ALPCO Announces Deadline for Winter 2020 Diabetes Research Travel Grant Award
ALPCO announced the submission deadline for its Winter 2020 Diabetes Research Travel Grant Award. Each recipient is awarded up to $2500 to present their research at a relevant conference and a $2500 product credit. - December 04, 2019 - ALPCO
Good News: a Panel of TGF-Beta and TGF-Beta Receptor Antibodies is Created by Abbomax
TGF-β regulates multiple biological processes, including embryonic development, adult stem cell differentiation, proliferation, homeostasis, immune regulation, wound healing, and inflammation. Multiple cells synthesize TGF-β and many cells have specific receptors for this peptide. AbboMax created a panel of TGF-β and TGF-β receptors antibodies. AbboMax, Inc. has been developing & manufacturing antibodies, FFPE cell pellets slides, for many years in California. - November 23, 2019 - AbboMax, Inc.
AMT Introduces UriCap for Patients in Long-Term Care - Innovative External Urine Collection Device Improves Quality of Care and Reduce Facility Costs
American Medical Technologies (AMT), the leading independent provider of wound care solutions for long-term care and post-acute environments, has partnered with TillaCare to introduce UriCap, an innovative external urine collection device for managing female urinary incontinence (UI) in the... - November 23, 2019 - American Medical Technologies
AT-1501, a Drug Discovered at the ALS Therapy Development Institute, Completes Phase I Trials
The ALS Therapy Development Institute (ALS TDI), a non-profit biotechnology company dedicated to the discovery and development of effective treatments for ALS, is pleased to share that AT-1501, a drug discovered and developed in the ALS TDI lab, has successfully completed Phase I clinical trials. - November 20, 2019 - ALS Therapy Development Institute
Nuriv® Delivers Impressive Lineup of Patented CBD Formulations
Nuriv® releases patented CBD formulations: RELAX, SLEEP, JOINT, along with its stand-alone CBD products, Hazelnut, Chocolate Brownie and French Vanilla. These release a powerfull Micellized form of CBD in amazing flavors, such as Peanut Butter Cup and Chocolate Brownie. Micellized compounds that are water insoluble absorb quicker, half speedy onset and improved Pharmacokinetics. 20mg CBD per 10ml serving and 22 servings per 8oz. - November 20, 2019 - VIRUN
Phase III Clinical Study of Valbenazine for Chorea in Huntington Disease
Huntington Study Group Announces Initiation of Phase III Clinical Study of Valbenazine for the Treatment of Chorea Associated with Huntington Disease. - November 14, 2019 - Huntington Study Group
Bold Health Partners with the University of Pennsylvania for Clinical Trial of Its Zemedy IBS App
The School of Arts and Science of the prestigious University of Pennsylvania has tendered a public invitation for suitable individuals to participate in a waitlist randomised control trial aimed at investigating the potential benefits of the Zemedy mobile app in patients with Irritable Bowel... - November 13, 2019 - Bold Health
Global Regenerative Group Enters Into Distribution Partnership with Aurafix & Remodem
Global Regenerative Group, a proven company in the field of medicine and innovation, is pleased to announce partnerships with Remodem and Aurafix. - November 09, 2019 - Global Regenerative Group
ALPCO Launches Analytically Specific Human and Rodent STELLUX® Glucagon ELISA
ALPCO's new STELLUX® Chemiluminescence Glucagon ELISA features increased analytical specificity and a broad range to accurately quantify glucagon levels between 0.86 and 143.7 pmol/L (3-500 pg/mL) in human and rodent samples. - November 06, 2019 - ALPCO
NuvOx Pharma US Patent Issuance - Radiotherapy and Chemotherapy with an Oxygen Therapeutic
NuvOx Pharma, Inc, a clinical stage biopharmaceutical company developing NanO2TM emulsion for oxygen delivery today announced the issuance of US Patent 10,456,468 – Fractionated Radiotherapy and Chemotherapy with an Oxygen Therapeutic. NanO2TM emulsion is designed to increase tumor oxygen... - November 03, 2019 - NuvOx Therapeutics
Alzheimer’s Stem Cell Study to Renew by Alzheimer’s Awareness Month
MD Stem Cells plans to continue ACIST Alzheimer’s, Autism, Dementia study at least additional year. - October 31, 2019 - MD Stem Cells
ALPCO’s New Fecal Calprotectin ELISA with Superior Clinical Accuracy Receives FDA 510(k) Clearance
ALPCO received 510(k) clearance from the US FDA for its new fecal Calprotectin Chemiluminescence ELISA test. The ALPCO Calprotectin Chemiluminescence ELISA’s superior clinical accuracy will enable clinical laboratories to provide the most accurate results to gastroenterologists facing the challenges of differentiating IBD from IBS. - October 30, 2019 - ALPCO
CADASIL Eligibility in the NEST Neurologic Stem Cell Treatment Study
MD Stem Cells reports how hereditary stroke syndrome may benefit. - October 30, 2019 - MD Stem Cells
Aciont Issued Key Patent Covering the Novel Design of the Visulex Ocular Drug Delivery Device
Aciont was issued a U.S. patent that covers an important aspect of the novel design of its main Visulex ocular drug delivery system which has been tested for safety and efficacy in its lead clinical program under U.S. IND. - October 12, 2019 - Aciont Inc.
Omni Health Announces CEO Resignation
Omni Health, Inc., (OTC: OMHE) Andrey Soloviev announces his resignation from the position of CEO of Omni Health, Inc. effective 08/20/2019. Safe Harbor Statement Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that... - September 27, 2019 - Omni Health
Cayman Awarded 1.5 Million Dollar SBIR Grant
The NIH’s National Institute of Arthritis and Musculoskeletal & Skin Diseases (NIAMS) has awarded Cayman Chemical with a Phase II Small Business Innovation Research (SBIR) grant to develop its patented small molecule bone repair agent KMN-159. - September 25, 2019 - Cayman Chemical Company
Thrivous Upgrades Clarity Daily Nootropic with Synapsa
Thrivous, the human enhancement company, has launched Formula 3 of Clarity Daily Nootropic. Formula 3 incorporates Synapsa, a standardized and patented form of bacopa monnieri that has been the subject of more than 30 years of clinical study for memory support. While most cognitive health... - September 25, 2019 - Thrivous
Oncoheroes Biosciences Inc. and Boehringer Ingelheim International GmbH Sign Exclusive Licensing Agreement for Volasertib
Oncoheroes Biosciences Inc (“Oncoheroes”) and Boehringer Ingelheim International GmbH (“Boehringer Ingelheim”) have signed a worldwide, exclusive licensing agreement for volasertib, an investigational anti-cancer compound that was originally discovered and developed by... - September 19, 2019 - Oncoheroes Biosciences Inc.
Thrivous Upgrades Alpha with Phosphatidylserine for Healthy Brain Aging
Thrivous, the human enhancement company, has upgraded Alpha, the neuroprotector, to include phosphatidylserine. Alpha is a cognitive longevity enhancement supplement that Thrivous developed to support healthy brain aging. Thrivous designed formula 2 of Alpha to enhance its efficacy, enabled by... - September 19, 2019 - Thrivous
Scintica Instrumentation and Aspect Imaging Announce Exclusive Agreement for Pre-Clinical MRI Imaging Products
Scintica Instrumentation Inc. is excited to announce its exclusive distribution agreement with Aspect Imaging for the M-Series(TM) MRI systems for scientific research. With more than 100 MRI installations worldwide, Aspect’s compact MRI systems are self-shielding, cryogen free and do not need... - September 18, 2019 - Scintica Instrumentation
DNAtix Launches Free Anonymous Genetic Vault
Digital DNAtix Ltd., the Israeli cyber genetics startup, has announced the first free anonymous genetic vault service. DNAtix developed the Cyber Genetics Smart Platform for Digital Genetics. Lack of privacy is currently a barrier for so many people who want to have their DNA tested but are afraid to give their genetic data away. As of today anyone can anonymously upload their raw file from 23&Me and Ancestry.com onto the DNAtix platform. - September 17, 2019 - Digital DNAtix Ltd.
Cambridge Cider Social Invites You to Celebrate Autumn by Tasting Hard Ciders and Donuts at a Fun Outdoor Festival
On October 24, 2019 join the ALS Therapy Development Institute in Cambridge for an outdoor celebration of autumn with hard cider, apple cider donuts, seasonal snacks, music, and fun – all in support of a great cause. - September 10, 2019 - ALS Therapy Development Institute
Paras Biopharmaceuticals Successfully Develops Cytofold StructQuant® Technology for Cytoplasmic Disulphide Formation, (for Active Folding) for Complex Therapeutic Protein
Paras Biopharmaceuticals Finland Oy is pleased to announce that its proprietary technology, Cytofold StructQuant®, is established for the high-level expression of homogeneously folded disulfide bond containing proteins in the cytoplasm of E. Coli. The technology offers all cost benefits of... - September 10, 2019 - Paras Biopharmaceuticals Finland Oy
FDA Grants Vascular BioSciences Humanitarian Use Device (HUD) Designation to the Endoarterial Biopsy Catheter for Group 1 Pulmonary Arterial Hypertension
Vascular Biosciences (VBS) is pleased to announce the receipt of a Humanitarian Use Device (HUD) designation from the U.S. Food and Drug Administration (FDA) for the Endoarterial Biopsy Catheter (EABC) to take pulmonary artery biopsies in patients who have Group 1 pulmonary arterial hypertension... - September 06, 2019 - Vascular BioSciences, Inc
Global Regenerative Group & Kanfit3D Enter Into Distribution Partnership
Pleased to announce a new distribution partnership between Global Regenerative Group, a company which has developed extensive experience in the most advanced medical device industries, and Kanfit3D. - September 05, 2019 - Global Regenerative Group
Biosynthetic Technologies Inks Patent License Agreement with Cayman Chemical for the Global Pharmaceutical and R&D Markets
Biosynthetic Technologies (BT) today announced it has signed on with Cayman Chemical for the production and distribution of novel Estolide compounds for pharmaceutical testing applications. BT is excited to partner with Cayman Chemical to provide discovery and pre-clinical development services to... - September 05, 2019 - Cayman Chemical Company
Thrivous Earns Better Business Bureau Accreditation
Better Business Bureau (BBB) of Utah has accredited Thrivous. After review, BBB determined that Thrivous meets its Standards for Trust: build trust, advertise honestly, tell the truth, be transparent, honor promises, be responsive, safeguard privacy, and embody integrity. Thrivous has committed to... - September 04, 2019 - Thrivous
CrystalGenomics Receives Orphan Drug Designation from the US FDA for CG-745 in Pancreatic Cancer
CrystalGenomics, Inc. (KOSDAQ: 083790) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CG-745, a clinical stage histone deacetylase (HDAC) inhibitor being developed for several hematologic malignancies and solid tumors, for the treatment of... - August 30, 2019 - CrystalGenomics, Inc.
Dr. David Dayton Joins Thrivous Science Advisor Board
Dr. David Dayton has joined the science advisor board at Thrivous, the human enhancement company. The board informs ongoing product and service development, reflecting Thrivous' commitment to guidance from consensus science in its mission to help customers access technology with the greatest... - August 28, 2019 - Thrivous
Thrivous Upgrades Clarity with Bioavailable Vitamin B Complex
Thrivous, the human enhancement company, has upgraded Clarity, the daily nootropic, to include bioavailable Vitamin B Complex. Clarity is a cognitive enhancement supplement that Thrivous developed to improve focus, memory, and mood. Thrivous designed formula 2 of Clarity to support brain function... - August 21, 2019 - Thrivous
Zifo RnD Solutions and Scilligence Announce Strategic Partnership
Zifo RnD Solutions and Scilligence Corporation announce a strategic partnership that enables Zifo to provide System Integrations Solutions for Scilligence suite of integrated informatics solutions. The partnership will help clients to easily select, evaluate, and implement solutions that fit their... - August 18, 2019 - Zifo
New Research Benchmarks Clinical Investigator Satisfaction with Pharma Sponsors and Central Laboratories
8-year Study Tracks Central Lab Performance and Identifies Covance as Leading the Way in Clinical Investigator Satisfaction. - August 13, 2019 - Life Science Strategy Group, LLC
Thrivous Launches Alpha, the Extended Daily Nootropic
Thrivous, the human enhancement company, has developed and brought to market Alpha, the extended daily nootropic. Alpha is designed for daily use to support long-term brain function. It is also designed to complement Clarity, Serenity, and Surge, nootropics previously developed and brought to... - August 11, 2019 - Thrivous
Arteric Named a Top 100 Healthcare Marketing Agency by MM&M
Latest accolade follows a year of 30% revenue growth and thought leadership. - August 09, 2019 - Arteric
Advances in Medicine Cause New, Groundbreaking Drug by Quantum Genomics (QNNTF) to Help with Chronic Hypertension
Quantum Genomics are the creators of Firibastat, a first-in-class brain aminopeptidase inhibitor (BAPAI) that could potentially treat treatment-resistant hypertension by acting in the brain to interfere with the renin-angiotensin system. It is estimated that there are around 150 million people... - August 05, 2019 - Quantum Genomics